Genitourinary Cancers | Specialty

Dr. Hristos Kaimakliotis on Predictive Markers in Bladder Cancer

July 22nd 2016

Dr. Haseebuddin on PD-1 Expression on Monocytes in RCC

July 21st 2016

Mohammed Haseebuddin, MD, a fellow in Urologic Oncology at Fox Chase Cancer Center, discusses the overall significance of a study examining an elevated preoperative classical monocyte PD-1 mean fluorescence intensity level in patients with clear cell renal cell carcinoma.

Dr. Randy Sweis on Impact of Atezolizumab Approval in Bladder Cancer

July 15th 2016

Expert Shares Potential of Durvalumab in Patients With Urothelial Bladder Cancer

July 15th 2016

Saeed Rafii, MD, PhD, MRCP, discusses the PD-L1 inhibitor durvalumab, the encouraging findings of it in Study 1108, and the evolving landscape of bladder cancer.

Dr. Pal on Biomarker Development in Renal Cell Carcinoma

July 15th 2016

Sumanta Kumar Pal, MD, assistant clinical professor, Department of Medical Oncology and Therapeutics Research, co-director, Kidney Cancer Program, City of Hope, discusses biomarker development in the field of renal cell carcinoma (RCC).

Dr. Elizabeth Plimack on Nivolumab in Kidney Cancer

July 15th 2016

O'Donnell Discusses IMvigor Findings, Excitement Over Atezolizumab Approval in mUC

July 14th 2016

Peter O'Donnell, MD, discusses the encouraging IMvigor 210 results, the impact of atezolizumab (Tecentriq) in the treatment landscape, and the role of immunotherapy in metastatic urothelial carcinoma.

Dr. Rosenberg on Future Use of Atezolizumab in Bladder Cancer

July 13th 2016

Jonathan E. Rosenberg, MD, medical oncologist, Memorial Sloan Kettering Cancer, discusses ongoing research of and next steps with atezolizumab (Tecentriq) for the treatment of patients with metastatic urothelial carcinoma.

Dr. McDermott on Long-Term Benefit With Nivolumab in RCC

July 12th 2016

David F. McDermott, MD, associate professor of Medicine, Harvard Medical School, staff physician, director, Biologic Therapy and Cutaneous Oncology Programs, Hematology/Oncology, Beth Israel Deaconess Medical Center, discusses long-term follow-up results of treatment with nivolumab (Opdivo) for patients with renal cell carcinoma (RCC).

Adjuvant Sunitinib Improves DFS in Renal Cell Carcinoma

July 9th 2016

Sunitinib (Sutent) extended disease-free survival versus placebo as an adjuvant therapy for patients with renal cell carcinoma at high risk of recurrence in the phase III S-TRAC trial.

Dr. Jorge Garcia on METEOR Trial for RCC

July 7th 2016

Jorge A. Garcia, MD, Department of Hematology and Oncology, discusses the results of the phase III METEOR trial, which compared the efficacy of cabozantinib (Cabometyx) versus everolimus (Afinitor) in patients with advanced renal cell carcinoma.

Dr. Nanus on Next Steps With Atezolizumab in Patients With mUC

July 7th 2016

David M. Nanus, MD, medical oncologist, Weill Cornell Medicine and NewYork-Presbyterian Hospital, discusses the unanswered questions that remain with atezolizumab (Tecentriq) in patients with metastatic urothelial carcinoma (mUC).

GU Cancer Treatments Advance, But Their Application Remains Unclear

July 5th 2016

Even as our understanding of the biology of prostate and bladder cancers improves and treatment protocols are refined, there remain many clinical scenarios in which no clear-cut answers are available.

A Look to the Future in RCC

June 29th 2016

A Changing Landscape in RCC

June 29th 2016

Novel Approaches in Advanced RCC

June 29th 2016

Long-Term RCC Data with Nivolumab

June 29th 2016

Second and Third-Line Decisions in RCC

June 29th 2016

The Role of Lenvatinib in Advanced RCC

June 29th 2016

Options in the Third Line Setting for RCC

June 29th 2016